Home New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer
 

Keywords :   


New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer

2015-09-08 07:25:25| drugdiscoveryonline Home Page

Bristol-Myers Squibb Company recently announced updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC)

Tags: with advanced cell treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Delayed implementation of EID eartag rule requested
More »